Kristina Burow Biography and Net Worth

Director of Scholar Rock

Kristina Burow has served as a member of our board of directors since August 2014. Ms. Burow has served as Managing Director of ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical companies. She previously was a co-founder and member of the board of directors of Receptos, Inc., (acquired by Celgene Corporation). Ms. Burow has participated in a number of other ARCH portfolio companies including KYTHERA Biopharmaceuticals, Inc. (acquired by Allergan), and Ikaria, Inc. (acquired by Mallinckrodt). Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a BS in Chemistry from the University of California, Berkeley, an MA in Chemistry from Columbia University, and an MBA from the University of Chicago.

What is Kristina Burow's net worth?: The estimated net worth of Kristina Burow is at least $273.62 million as of October 27th, 2025. Ms. Burow owns 6,046,907 shares of Scholar Rock stock worth more than $273,622,542 as of December 4th. This net worth evaluation does not reflect any other assets that Ms. Burow may own. Learn More about Kristina Burow's net worth.
How do I contact Kristina Burow?: The corporate mailing address for Ms. Burow and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Kristina Burow's contact information.
Has Kristina Burow been buying or selling shares of Scholar Rock?: Kristina Burow has not been actively trading shares of Scholar Rock during the last quarter. Most recently, Kristina Burow sold 5,400 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.72, for a transaction totalling $160,488.00. Following the completion of the sale, the director now directly owns 21,071 shares of the company's stock, valued at $626,230.12. Learn More on Kristina Burow's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 10/6/2025.

Kristina Burow Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/29/2025	Sell	5,400	$29.72	$160,488.00	21,071

Kristina Burow Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $45.20

$42.83

$45.50

50 Day Range

MA: $34.97

$27.92

$45.20

2 Week Range

Now: $45.20

$22.71

$46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61